SINGULAIR 4 MG 14 CHEWABLE TAB

* SINGULAIR (Montelukast) 4 mg Paediatric 14 Chewable Tablets.
* Composition: Each tablet contains:
& & 4.2 mg montelukast sodium equivalent to 4 mg montelukast. Also includes mannitol (E421) and aspartame (E951), equivalent to
& & 0.674 mg phenylalanine.
* Indications: Singulair is indicated in adult and pediatric patients 6 months of age and older for the prophylaxis && chronic treatment
& & of asthma, including the prevention od day- and nighttime symptoms, th treatment of aspirin-sensitive asthmatic patients,
& & and the prevention of excercise-induced bronchoconstriction. Singulair is indicated for the relief of daytime and nighttime symptoms
& & of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older).
* Dosage && Administration: As directed by physician. Consult the enclosed package circular before use.
& & – Singulair should be taken once daily. For asthma, the dose should be taken in the evening. For allegic rhinitis, the time of
& & administration may be individualized to suit patient needs.
& & – Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
& & – Adults 15 years of age and older with asthma and/or seasonal allergic rhinitis: one 10-mg tablet daily.
& & – Pediatric patients 6 to 14 years of age with asthma and/or seasonal allergic rhinitis: 5-mg chewable tablet daily.
& & – Pediatric patients 2 to 5 years of age with asthma and/or seasonal allergic rhinitis: one 4-mg chewable tablet daily or one packet
& & of 4-mg oral granules daily.
& & – Pediatric patients 6 months to 2 years of age with asthma: one packet of 4-mg oral granules daily.
* Do not store above 30 degrees C. Store in the original container to protect from moisture and light.
* MSD (Merck Sharp && Dohme Limited) – UK. Imported by: Soficopharm. استيراد سوفيكو فارم
& & Registered trademark of Merck && Co. Inc., Whitehouse Station, N.J., USA.